Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMARCA2 | P51531 | 9/20 | 0.41 |
| ▸ | SMARCA4 | P51532 | 8/20 | 0.41 |
| ▸ | GRM5 | P41594 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | ATR | Q13535 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | KDM5A | P29375 | 1/20 | 0.35 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.33 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27671792 | 0.86 | GRM5 (0.40) | SMARCA2SMARCA4GRM5KDM4EALDH1A1 | |
| SCHEMBL1459501 | 0.84 | CCNC (0.44) | SMARCA2SMARCA4GRM5KDM4EALDH1A1 | |
| SCHEMBL2326367 | 0.81 | GRM5 (0.34) | SMARCA2SMARCA4GRM5KDM4EALDH1A1 | |
| SCHEMBL25216054 | 0.81 | AR (0.45) | GRM5KDM4EALDH1A1CNR2KDM5A | |
| SCHEMBL17503398 | 0.78 | ALDH1A1 (0.37) | SMARCA2SMARCA4KDM4EALDH1A1KDM5A | |
| SCHEMBL1400929 | 0.78 | ALDH1A1 (0.46) | SMARCA2SMARCA4GRM5KDM4EALDH1A1 | |
| SCHEMBL1163343 | 0.77 | ALDH1A1 (0.41) | SMARCA2SMARCA4GRM5ALDH1A1 | |
| SCHEMBL1137155 | 0.77 | SMARCA2 (0.33) | SMARCA2SMARCA4GRM5ALDH1A1AR | |
| SCHEMBL3831425 | 0.75 | CHRM5 (0.41) | KDM4E | |
| SCHEMBL1351820 | 0.75 | KMT2A (0.46) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8008317-B2 | Inhibitors of akt activtiy | MERCK SHARP & DOHME CORP. (US) | 2011-08-30 | — | — | US | disclosed |
| US-7910561-B2 | Cancer; such as 3-phenyl-2-(4-{[4-(5-pyridin-2-yl-1H-1,2,4-triazol-3-yl)piperidin-1-yl]methyl}phenyl)-1,6-naphthyridin-5(6H)-one; serine/threonine kinase (Akt) suppression; increased cellular potency or solubility, greater selectivity, enhanced pharmacokinetic properties, lack of off target activity | MERCK SHARP & DOHME CORP. (US) | 2011-03-22 | — | — | US | disclosed |
| EP-1814871-B1 | COMPOUNDS THAT MODULATE PPARY TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | GALDERMA RES & DEV (FR) | 2011-03-02 | — | — | EP | disclosed |
| US-20040235867-A1 | Tyrosine kinase inhibitors | BILODEAU MARK T (US) | 2004-11-25 | — | — | US | disclosed |
| WO-2003009852-A1 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2003-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235867-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | SMARCA2 3808/4885SMARCA4 3542/4885GRM5 1726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.